Modelling Propofol pharmacokinetics and pharmacodynamics during an intravenous anaesthesia guided by the bispectral index (Bis)

Dados básicos

Código:
Estudo Clínico Académico
Protocolo:
Estudo Clínico Académico
EUDRACT:
NCT:
Centro:
Dotação:
Ano de início:
2021
Ano de conclusão:
Estudos observacionais Nacional Não Financiado Outros

Objectivos do projeto

Estudos Observacionais (STROBE statement); Natureza do Promotor: Academia – Tipo não comercial – Iniciativa do Investigador; Tipo de Centro: Unicêntrico – Cuidados Secundários

Documentos

  • Não há documentos

Participantes

Unidades de investigação

Stakeholders - Promotores

FMUP

Outputs do ensaio clínico


In vitro and in vivo anti-epileptic efficacy of eslicarbazepine acetate in a mouse model of KCNQ2-related self-limited epilepsy

Monni, L; (...); Fidzinski, P

Article. 10.1111/bph.15689. 2022

  • Open Access.

Absorption, metabolism and excretion of opicapone in human healthy volunteers

Loureiro, AI; (...); Soares-da-Silva, P

Article. 10.1111/bcp.15383. 2022

  • Open Access.

ADOPTION Study: Status update of a Randomised, Open-Label Exploratory Trial of Opicapone in Parkinson's Disease

Ferreira, J.; (...); Soares-da-Silva, P.

Meeting Abstract. 2022


ADOPTION Study: Status Update of a Randomised, Open-Label Exploratory Trial of Opicapone in Parkinson's Disease

Ferreira, J.; (...); Soares-da-Silva, P.

Meeting Abstract. 2022


Boosting caffeic acid performance as antioxidant and monoamine oxidase B/catechol-O-methyltransferase inhibitor

Chavarria, D; (...); Borges, M.

Article. 10.1016/j.ejmech.2022.114740. 2022


Cellular and Mitochondrial Toxicity of Tolcapone, Entacapone, and New Nitrocatechol Derivatives

Pinto, M; (...); Borges, F

Article. 10.1021/acsptsci.4c00124. 2024

  • Open Access.

Design of a double-blind, randomized, phase II trial in the prevention of epilepsy in stroke: anti-epileptogenic effects of eslicarbazepine acetate

Koepp, Matthias; (...); Soares-da-Silva, Patricio

Meeting Abstract. 2021


Dopamine-beta-hydroxylase Short Interfering Nucleic Acid Overcomes the Short-term Efficacy of Timolol and Bimatoprost in Noradrenergic Overactivated Glaucomatous Eye

Carneiro, C.; (...); Soares-da-Silva, P.

Meeting Abstract. 2023


Drug-Drug Interaction between Oral Zamicastat and Continuous Epoprostenol Infusion at Steady-State Conditions in Healthy Subjects

Fonseca, Marlene; (...); Soares-da-Silva, Patricio

Article. 10.1002/jcph.2486. 2024


Drug-drug interaction study between zamicastat and furosemide in healthy subjects

Santos, Ana; (...); Soares-Da-Silva, Patricio

Meeting Abstract. 10.1183/13993003.congress-2021.PA1930. 2021


Effect of Toll-like receptor-2, -4, -5, -7, and NOD2stimulation on potassium channel conductance in intestinal epithelial cells (vol 323, pg G410, 2022)

Cosme, D., Soares-da-Silva, P., Magro, F.

Correction. 10.1152/ajpgi.00139.2023_COR. 2023


Effect of Toll-like receptor-2,-4,-5,-7, and NOD2 stimulation on potassium channel conductance in intestinal epithelial cells

Cosme, Dina, Soares-da-Silva, Patricio, Magro, Fernando

Article. 10.1152/ajpgi.00139.2022. 2022


Effect of zamicastat on blood pressure and heart rate response to cold pressor test: A double-blind, randomized, placebo-controlled study in healthy subjects

Fonseca, M; (...); Soares-da-Silva, P

Article. 10.1111/bcp.16167. 2024


Effectiveness of opicapone in Parkinson's disease patients with motor fluctuations according to baseline use of dopamine agonists: Findings from the real-world OPTIPARK study

Jost, Wolfgang; (...); Soares-Da-Silva, Patricio

Meeting Abstract. 10.1016/j.jns.2021.119432. 2021


Effectiveness of opicapone in Parkinson's disease patients with motor fluctuations according to baseline use of entacapone: findings from the real-world OPTIPARK study

Jost, W.; (...); Soares-da-Silva, P.

Meeting Abstract. 2021


Effectiveness of opicapone in Parkinson's disease patients with motor fluctuations according to baseline use of entacapone: Findings from the real-world OPTIPARK study

Jost, Wolfgang; (...); Soares-Da-Silva, Patricio

Meeting Abstract. 10.1016/j.jns.2021.119439. 2021


Effectiveness of opicapone in Parkinson's disease patients with motor fluctuations according to baseline use of monoamine-oxidase-B inhibitors (MAO-B) and dopamine agonists (DA): findings from the real-world OPTIPARK study

Reichmann, H.; (...); Soares-da-Silva, P.

Meeting Abstract. 2021


Effectiveness of opicapone in Parkinson's disease patients with motor fluctuations according to baseline use of monoamine-oxidase-b inhibitors and dopamine agonists: The real-world OPTIPARK study

Reichmann, Heinz; (...); Soares-Da-Silva, Patricio

Meeting Abstract. 10.1016/j.jns.2021.119433. 2021


Effectiveness of opicapone in Parkinson's disease patients with motor fluctuations according to baseline use of safinamide: findings from the real-world OPTIPARK study

Pavese, N.; (...); Soares-da-Silva, P.

Meeting Abstract. 2021


Effectiveness of opicapone in Parkinson's disease patients with motor fluctuations according to baseline use of safinamide: Findings from the real-world OPTIPARK study

Pavese, Nicola; (...); Soares-Da-Silva, Patricio

Meeting Abstract. 10.1016/j.jns.2021.119427. 2021


Effects of Opicapone on Sleep in Patients with Parkinson's Disease and Motor Fluctuations

Hauser, R.; (...); Klepitskaya, O.

Meeting Abstract. 2021


Efficacy of opicapone according to different levodopa daily intakes in Parkinson's disease patients with motor fluctuations

Ebersbach, G.; (...); Soares-da-Silva, P.

Meeting Abstract. 2021


Efficacy of opicapone according to different levodopa daily intakes in Parkinson's disease patients with motor fluctuations

Ebersbach, Georg; (...); Soares-Da-Silva, Patricio

Meeting Abstract. 10.1016/j.jns.2021.119446. 2021


Efficacy of opicapone according to levodopa's duration of use in Parkinson's disease patients with motor fluctuations

Antonini, A.; (...); Soares-da-Silva, P.

Meeting Abstract. 2021


Efficacy of opicapone according to levodopa's duration of use in Parkinson's disease patients with motor fluctuations

Antonini, Angelo; (...); Soares-Da-Silva, Patricio

Meeting Abstract. 10.1016/j.jns.2021.119450. 2021


Efficacy of opicapone at different levodopa regimens up to a threshold of 600 mg/day levodopa in Parkinson's disease patients with motor fluctuations

Lewitt, Peter; (...); Soares-Da-Silva, Patricio

Meeting Abstract. 10.1016/j.jns.2021.119445. 2021


Gene silencing of LAT1 and ASCT2 Transporters via Short Interfering Nucleic Acid Therapies upon Human Colon Cancer HCT-116 Cell Xenografts

Carneiro, C.; (...); Soares-da-Silva, P.

Meeting Abstract. 2023


Impact of 3-month earlier versus later initiation of opicapone versus entacapone in levodopa-treated patients with Parkinson's disease and motor fluctuations

Carroll, Camille; (...); Soares-Da-Silva, Patricio

Meeting Abstract. 10.1016/j.jns.2021.119447. 2021


Impact of 3-month earlier versus postponed initiation of opicapone versus entacapone in levodopa-treated patients with Parkinson's disease and motor fluctuations

Carroll, C.; (...); Soares-da-Silva, P.

Meeting Abstract. 2021


Inactivation Mechanism of the Fatty Acid Amide Hydrolase Inhibitor BIA 10-2474

Cerqueira, Nuno M. F. S. A.; (...); Palma, P. Nuno

Article. 10.1002/cbic.202200166. 2022


Influence of demographic characteristics on the effectiveness of opicapone in Parkinson's disease patients with motor fluctuations: findings from the real-world OPTIPARK study

Mohamed, B.; (...); Soares-da-Silva, P.

Meeting Abstract. 2021


Influence of demographic characteristics on the effectiveness of opicapone in Parkinson's disease patients with motor fluctuations: Findings from the real-world OPTIPARK study

Mohamed, Biju; (...); Soares-Da-Silva, Patricio

Meeting Abstract. 10.1016/j.jns.2021.119431. 2021


Influence of disease duration on the effectiveness of opicapone in Parkinson's disease patients with motor fluctuations: Findings from the real-world OPTIPARK study

Warnecke, Tobias; (...); Soares-Da-Silva, Patricio

Meeting Abstract. 10.1016/j.jns.2021.119440. 2021


Influence of levodopa daily dose on the effectiveness of opicapone in Parkinson's disease patients with motor fluctuations: Findings from the real-world OPTIPARK study

Carrolla, Camille; (...); Soares-Da-Silva, Patricio

Meeting Abstract. 10.1016/j.jns.2021.119426. 2021


Influence of onset of motor fluctuations on the effectiveness of opicapone in Parkinson's disease patients with motor fluctuations: findings from the real-world OPTIPARK study

Jost, W.; (...); Soares-da-Silva, P.

Meeting Abstract. 2021


Influence of onset of motor fluctuations on the effectiveness of opicapone in Parkinson's disease patients with motor fluctuations: Findings from the real-world OPTIPARK study

Jost, Wolfgang; (...); Soares-Da-Silva, Patricio

Meeting Abstract. 10.1016/j.jns.2021.119425. 2021


Levodopa Pharmacokinetics in Different Levodopa Treatment Regimens plus Opicapone in Parkinson's Disease

Ferreira, J.; (...); Soares-da-Silva, P.

Meeting Abstract. 2022


Levodopa Pharmacokinetics in Different Levodopa Treatment Regimens plus Opicapone in Parkinson's Disease Patients with Motor Fluctuations

Ferreira, J.; (...); Soares-da-Silva, P.

Meeting Abstract. 2022


Long-term effect of Toll-like receptor-2,-4,-5,-7 and NOD2 stimulation on Na plus , K plus -ATPase activity and expression in intestinal epithelial cells

Cosme, D, soares-da-silva, p, Magro, F

Article. 10.1152/ajpcell.00208.2022. 2023


Long-term efficacy of opicapone in the reduction of on-time with troublesome dyskinesia in Parkinson's disease patients with motor fluctuations and reporting troublesome dyskinesia

Stocchi, Fabrizio; (...); Soares-Da-Silva, Patricio

Meeting Abstract. 10.1016/j.jns.2021.119442. 2021


Metabolism and disposition of opicapone in the rat and metabolic enzymes phenotyping

Loureiro, I, Ana; (...); Soares-da-Silva, Patricio

Article. 10.1002/prp2.891. 2022

  • Open Access.

Metabolism and disposition of zamicastat in rats.

Araújo F; (...); Loureiro AI

Article. 10.1080/00498254.2024.2411993. 2024


OCEAN Study in Parkinson's Disease: Status Update of a Randomised Double-Blind Placebo-Controlled Trial of Opicapone

Chaudhuri, K.; (...); Soares-da-Silva, P.

Meeting Abstract. 2022


Off-Time and Sleep in Patients with Parkinson's Disease and Motor Fluctuations

Hauser, Robert A.; (...); Klepitskaya, Olga

Meeting Abstract. 2021


Open-Label, Single-Arm, Exploratory Trial of Opicapone: Status Update of the OASIS (OPICAPONE IN SLEEP DISORDER) Study

Costa, R.; (...); Soares-da-Silva, P.

Meeting Abstract. 2022


Open-Label, Single-Arm, Exploratory Trial of Opicapone: Status Update of the OASIS (OPICAPONE IN SLEEP DISORDER) Study

Costa, R.; (...); Soares-da-Silva, P.

Meeting Abstract. 2022


Opicapone Analysis of Health Economic Costs in Clinical Practice in Parkinson's Disease UK Patients with Motor Fluctuations: Findings from the OPTIPARK Study

Lees, A.; (...); Soares-da-Silva, P.

Meeting Abstract. 2021


Opicapone analysis of health economic costs in clinical practice in Parkinson's disease UK patients with motor fluctuations: Findings from the OPTIPARK study

Lees, Andrew; (...); Soares-Da-Silva, Patricio

Meeting Abstract. 10.1016/j.jns.2021.119441. 2021


Opicapone in clinical practice in Parkinson's disease German patients with motor fluctuations: Findings from the OPTIPARK study

Reichmann, Heinz; (...); Soares-Da-Silva, Patricio

Meeting Abstract. 10.1016/j.jns.2021.119429. 2021


Opicapone in clinical practice in Parkinson's disease patients with motor fluctuations and complications of therapy at baseline: findings from the OPTIPARK study

Reichmann, H.; (...); Soares-da-Silva, P.

Meeting Abstract. 2021


Opicapone in clinical practice in Parkinson's disease patients with motor fluctuations and complications of therapy at baseline: Findings from the OPTIPARK study

Reichmann, Heinz; (...); Soares-Da-Silva, Patricio

Meeting Abstract. 10.1016/j.jns.2021.119451. 2021


Opicapone in Clinical Practice in Parkinson's Disease UK Patients with Motor Fluctuations: Findings from the OPTIPARK Study

Lees, A.; (...); Soares-da-Silva, P.

Meeting Abstract. 2021


Opicapone in clinical practice in Parkinson's disease UK patients with motor fluctuations: Findings from the OPTIPARK study

Lees, Andrew; (...); Soares-Da-Silva, Patricio

Meeting Abstract. 10.1016/j.jns.2021.119428. 2021


Opicapone in German Parkinson's disease patients with motor fluctuations: Results on WOQ-9, QoL and non-motor symptoms.

Reichmann, H.; (...); Soares-da-Silva, P.

Meeting Abstract. 2022


Opicapone in Parkinson's Disease German Patients with Motor Fluctuations: Findings from the OPTIPARK Study

Reichmann, H.; (...); Soares-da-Silva, P.

Meeting Abstract. 2021


Opicapone Use in Clinical Practice across Germany: A Sub-Analysis of the OPTIPARK Study in Parkinson's Disease Patients with Motor Fluctuations

Reichmann, H; (...); Soares-da-Silva, P

Article. 10.1159/000523771. 2022

  • Open Access.

Over-blending effect of lubricants on capsules manufacturing: a simple and fast wettability technique to predict batch dissolution performance

Barrocas, P.; (...); Vasconcelos, T.

Article. 10.1080/10837450.2023.2196332. 2023


Overcoming short term efficacy of timolol an bimatoprost in noradrenergic overactivated glaucomatous eye with chemically modified short interference nucleic acids targeting dopamine-beta-hydroxylase

Carneiro, Catarina; (...); Soares-da-Silva, Patricio

Meeting Abstract. 2023


PHASE 1 STUDY TO INVESTIGATE THE EFFECT OF P-GLYCOPROTEIN TRANSPORTER INHIBITION MEDIATED BY CARVEDILOL ON THE PHARMACOKINETICS OF ZAMICASTAT

Magalhaes, Luis; (...); Soares-da-Silva, Patricio

Meeting Abstract. 10.1016/j.chest.2021.07.2015. 2021

  • Open Access.

Redefining the strategy for the use of COMT inhibitors in Parkinson's disease: the role of opicapone

Jenner, P; (...); Soares-da-Silva, P

Review. 10.1080/14737175.2021.1968298. 2021

  • Open Access.

Safety of Eslicarbazepine Acetate in Elderly Versus Non-Elderly Patients with Focal Seizures: From Pooled Data of Clinical Studies to 8 Years of Post-Marketing Experience

Magalhaes, LM; (...); Soares-da-Silva, P

Article. 10.1007/s40264-021-01097-5. 2021

  • Open Access.

Salt-inducible kinases: new players in pulmonary arterial hypertension?

Antonio, Tatiana; (...); Gomes, Pedro

Review. 10.1016/j.tips.2022.06.008. 2022


SLEEP PATTERNS AND ``OFF''-TIME IN PATIENTS WITH PARKINSON'S DISEASE AND MOTOR FLUCTUATIONS

Hauser, Robert; (...); Klepitskaya, Olga

Meeting Abstract. 2022


Status Update of EPSILON: a Phase III, Randomised, Placebo-Controlled Study of Opicapone in Early Parkinson's Disease

Ferreira, J.; (...); Soares-da-Silva, P.

Meeting Abstract. 2022


Status Update of EPSILON: a Phase III, Randomised, PlaceboControlled Study of Opicapone in Early Parkinson's Disease

Ferreira, J.; (...); Soares-da-Silva, P.

Meeting Abstract. 2022


Study design to assess the effect of opicapone on levodopa pharmacokinetics in different levodopa-optimized treatment regimens in Parkinson's disease patients

Ferreira, Joaquim; (...); Soares-Da-Silva, Patricio

Meeting Abstract. 10.1016/j.jns.2021.119438. 2021


Study Design to Assess the Effect of Opicapone on Levodopa PK at Different Levodopa-Optimized Treatment Regimens in Parkinson's Disease Patients

Ferreira, J.; (...); Soares-da-Silva, P.

Meeting Abstract. 2021


The ADOPTION (eArly levoDopa with Opicapone in Parkinson's paTients wIth motOr fluctuatioNs) study in Parkinson's disease: design and rationale of a randomized prospective, open-label exploratory trial

Ferreira, J.; (...); Soares-da-Silva, P.

Meeting Abstract. 2021


The design of a multicentre, double-blind, randomized, placebo-controlled, Phase II trial in the prevention of epilepsy in stroke patients at high risk of unprovoked seizures: Anti-epileptogenic effects of eslicarbazepine acetate

Koepp, M.; (...); Soares-Da-Silva, P.

Meeting Abstract. 2022


The EPSILON (Early ParkinSon wIth L-dopa/DDCi and OpicapoNe) study in early Parkinson's disease: design and rationale of a phase III, double-blind, randomized, placebo-controlled study

Ferreira, J.; (...); Soares-da-Silva, P.

Meeting Abstract. 2021


The OASIS (OpicApone in Sleep dISorder) study in Parkinson's disease: design and rationale of an open-label, single-arm, pilot trial

Costa, R.; (...); Soares-da-Silva, P.

Meeting Abstract. 2021


The oasis (opicapone in sleep disorder) study in Parkinson's disease: Design and rationale of an open-label, single-arm, pilot trial

Costa, Raquel; (...); Soares-Da-Silva, Patricio

Meeting Abstract. 10.1016/j.jns.2021.119430. 2021


Voltage-clamp evidence of GABA(A) receptor subunit-specific effects: pharmacodynamic fingerprint of chlornordiazepam, the major active metabolite of mexazolam, as compared to alprazolam, bromazepam, and zolpidem

Fernandes, H; (...); Soares-da-Silva, P

Article. 10.1007/s43440-022-00411-x. 2022


Partilhar